BELIEF BIOMED
- Biotech or pharma, therapeutic R&D
BeliefBioMed is a biopharmaceutical company that dedicated to developing AAV-based gene therapy for patients living with serious diseases. BBM-H901 is China’s first approved gene therapy in April 2025. Besides the established collaborations with Takeda and Bayer, we are open to various forms of new collaborations, including asset licensing, Newco, platform cooperation on AAV capsids, co-development, and CDMO services. Based on our unique in house R&D capability, our R&D and manufacuturing cost of Gene therapy is extremely lower than the other competitors.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}